2. Search Result
Search Result
Results for "

PD-L1+inhibitor

" in MedChemExpress (MCE) Product Catalog:

81

Inhibitors & Agonists

1

Biochemical Assay Reagents

9

Peptides

7

Inhibitory Antibodies

4

Natural
Products

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19991
    BMS-1
    Maximum Cited Publications
    31 Publications Verification

    PD-1/PD-L1 inhibitor 1

    		 PD-1/PD-L1 Apoptosis Inflammation/Immunology Cancer
    BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM) [1] .
    BMS-1
  • HY-P9902A
    Pembrolizumab (anti-PD-1)
    5 Publications Verification

    MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)

    		 PD-1/PD-L1 Cancer
    Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 [1] .
    Pembrolizumab (anti-PD-1)
  • HY-172320
    BMS-986238

    		PD-1/PD-L1 Cancer
    BMS-986238 is an orally active macrocyclic peptide PD-L1 inhibitor. BMS-986238 can be used in the research of tumors such as solid tumors and lymphomas [1] .
    BMS-986238
  • HY-134884
    INCB086550
    2 Publications Verification

    PD-1/PD-L1-IN-8

    		 PD-1/PD-L1 Cancer
    INCB086550 is a potent, oral, small-molecule PD-L1 inhibitor with IC50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research [1].
    INCB086550
  • HY-124700
    LYPLAL1-IN-1
    1 Publications Verification

    		 Cyclic GMP-AMP Synthase STING PD-1/PD-L1 Epoxide Hydrolase Metabolic Disease
    LYPLAL1-IN-1 (compound 11) is a selective, covalent, and irreversible inhibitor of the lysophospholipase-like enzyme LYPLAL1 (IC50 = 6 nM). LYPLAL1-IN-1 shows selectivity against other serine hydrolases such as carboxylesterase CES1 (IC50 > 50 μM for CES1). LYPLAL1-IN-1 inhibits the depalmitoylation function of LYPLAL1, blocking its depalmitoylation modification of cyclic GMP-AMP synthase (cGAS), thereby promoting cGAS dimerization and activation, and initiating the cGAS-STING pathway-mediated innate immune response. LYPLAL1-IN-1 can enhance DNA-induced type I interferon production, upregulate PD-L1 expression in tumor cells, and promote the accumulation of tumor-infiltrating CD8 + T cells, with the core function of strengthening the anti-tumor immune response. LYPLAL1-IN-1 is primarily used in tumor immunology research, especially in combination with PD-1/PD-L1 inhibitors [1] .
    LYPLAL1-IN-1
  • HY-N0242
    Fraxinellone
    4 Publications Verification

    		 PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT Inflammation/Immunology Cancer
    Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1 [1].
    Fraxinellone
  • HY-N3431
    Kaempferol-7-O-rhamnoside

    		AMPK PD-1/PD-L1 FXR Reactive Oxygen Species (ROS) Cardiovascular Disease
    Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure [1] .
    Kaempferol-7-O-rhamnoside
  • HY-142221
    ARB-272572

    		PD-1/PD-L1 Cancer
    ARB-272572 is an oral effective small molecule PD-L1 inhibitor, with an IC50 value of 400 pM. ARB-272572 has research significance in tumors and chronic viral infections [1] .
    ARB-272572
  • HY-101097
    PD-1-IN-17

    		PD-1/PD-L1 Cancer
    PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM [1].
    PD-1-IN-17
  • HY-101058A
    PD1-PDL1-IN 1 TFA

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD1-PDL1-IN 1 TFA (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 TFA is useful as immune modulator [1].
    PD1-PDL1-IN 1 TFA
  • HY-P4072A
    (D)-PPA 1 TFA

    		PD-1/PD-L1 Cancer
    (D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy [1].
    (D)-PPA 1 TFA
  • HY-139781
    PD-L1-IN-1
    1 Publications Verification

    		 PD-1/PD-L1 Apoptosis Cancer
    PD-L1-IN-1 (Compound 10) is a potent PD-L1 inhibitor with an IC50 of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly exhibits low cytotoxicity in healthy cells [1].
    PD-L1-IN-1
  • HY-134886
    PD-1-IN-24

    		PD-1/PD-L1 Cancer
    PD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor [1].
    PD-1-IN-24
  • HY-167840
    IMMH-010 maleate

    		PD-1/PD-L1 Neurological Disease Cancer
    IMMH-010 maleate is a prodrug that serves as a novel PD-L1 inhibitor, exhibiting potential antitumor activity for the treatment of neurological disorders and advanced malignant solid tumors. IMMH-010 maleate is rapidly converted to its active form, YPD-29B, following oral administration. IMMH-010 maleate is poised for advancing research in the field of PD-L1 inhibitors and related therapeutic applications.
    IMMH-010 maleate
  • HY-P2478
    Human PD-L1 inhibitor V

    		PD-1/PD-L1 Inflammation/Immunology
    Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 [1].
    Human PD-L1 inhibitor V
  • HY-131347
    PD-1/PD-L1-IN-NP19

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects [1].
    PD-1/PD-L1-IN-NP19
  • HY-174830
    GJ19

    		PD-1/PD-L1 Cancer
    GJ19 is a PD-L1 inhibitor with an IC50 of 32.06 nM. GJ19 can effectively bind to human/murine PD-L1 protein with Kd values of 171 and 290 nM, respectively. GJ19 concentration-dependently promotes HepG2 cell mortality in a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells. GJ19 effectively suppresses tumor growth in a B16-F10 melanoma mouse model. GJ19 can be used for the study of tumor immunotherapy [1].
    GJ19
  • HY-132202
    PD-1/PD-L1-IN-10

    		PD-1/PD-L1 Apoptosis Cancer
    PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy [1].
    PD-1/PD-L1-IN-10
  • HY-P2477
    Human PD-L1 inhibitor IV

    		PD-1/PD-L1 Inflammation/Immunology
    Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a Kd value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 [1].
    Human PD-L1 inhibitor IV
  • HY-P990088
    Sotiburafusp alfa

    		VEGFR PD-1/PD-L1 Cardiovascular Disease
    Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker 101GGSGGSGGSGGSGGS 115 to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa also functions as a PD-L1 inhibitor and a VEGF inhibitor [1] .
    Sotiburafusp alfa
  • HY-155959
    PD-1/PD-L1-IN-33

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-33 (Compound N11) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC50: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity [1].
    PD-1/PD-L1-IN-33
  • HY-152240
    PD-1/PD-L1-IN-29

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-29 (S4-1) is a potent PD-1/PD-L1 inhibitor with an IC50 value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity [1].
    PD-1/PD-L1-IN-29
  • HY-W018597
    2-Chloro-N-methylethanamine hydrochloride

    		Biochemical Assay Reagents Others
    2-Chloro-N-methylethanamine hydrochloride is a nitro compound that can be used to synthesize PD-1 inhibitors [1].
    2-Chloro-N-methylethanamine hydrochloride
  • HY-P2470
    Human PD-L1 inhibitor II

    		PD-1/PD-L1 Cancer
    Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity [1].
    Human PD-L1 inhibitor II
  • HY-P2474
    Human PD-L1 inhibitor I

    		PD-1/PD-L1 Cancer
    Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a KD of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 [1].
    Human PD-L1 inhibitor I
  • HY-P4072
    (D)-PPA 1

    		PD-1/PD-L1 Cancer
    (D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy [1].
    (D)-PPA 1
  • HY-P2478A
    Human PD-L1 inhibitor V TFA

    		PD-1/PD-L1 Inflammation/Immunology
    Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 [1].
    Human PD-L1 inhibitor V TFA
  • HY-145239
    PD-1/PD-L1-IN-13

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8 + T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model [1].
    PD-1/PD-L1-IN-13
  • HY-175604
    SCL-1

    		PD-1/PD-L1 Cancer
    SCL-1 is an orally active anti-PD-1/PD-L1 inhibitor. SCL-1 can inhibit PD-1/PD-L1 binding. SCL-1 increases T cells, B cells and natural killer cells. SCL-1 exerts strong tumor growth inhibitory effects that were mediated by effector T-cell induction inside tumors and the up-regulated expression of long non-coding RNAs as neoantigens leading to cytotoxic T lymphocyte activation. SCL-1 can be used for the research of cancer, such as triple-negative breast cancer [1] .
    SCL-1
  • HY-179047
    SMU-L11-R

    		Toll-like Receptor (TLR) MyD88 IKK p38 MAPK ERK TNF Receptor Interleukin Related Inflammation/Immunology Cancer
    SMU-L11-R is a selective TLR7 agonist with an EC50 of 0.012 μM for human TLR7. SMU-L11-R specifically activates TLR7, recruits  MyD88, and triggers MAPK/NF-κB pathways, leading to TNF-α/IL-1β/IL-6 secretion in both mouse and human peripheral blood mononuclear cells. SMU-L11-R promotes M1-like macrophage polarization. SMU-L11-R exhibits excellent synergistic anti-tumor effects with PD-L1 inhibitors by upregulating CD8 +T cells. SMU-L11-R shows potential in colorectal cancer studies [1].
    SMU-L11-R
  • HY-P99799
    Pacmilimab

    CX-072

    		 PD-1/PD-L1 Cancer
    Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity [1].
    Pacmilimab
  • HY-P99887
    Pimivalimab

    JTX-4014

    		 PD-1/PD-L1 Cancer
    Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor [1].
    Pimivalimab
  • HY-P2564
    Human PD-L1 inhibitor III

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    Human PD-L1 inhibitor III is a human PD-L1 inhibitor.
    Human PD-L1 inhibitor III
  • HY-162343
    PD-1/PD-L1-IN-41

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/ PD-L1-in-41 (Compound 5c) is a PD-L1 and PD-1 inhibitor with IC50 value of 10.2 nM [1].
    PD-1/PD-L1-IN-41
  • HY-101058
    PD1-PDL1-IN 1

    		PD-1/PD-L1 Inflammation/Immunology
    PD1-PDL1-IN 1 (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 is useful as immune modulator [1].
    PD1-PDL1-IN 1
  • HY-179447
    PD-L1-IN-8

    		PD-1/PD-L1 Cancer
    PD-L1-IN-8 is a PD-L1 inhibitor (IC50 = 0.89 nM). PD-L1-IN-8 shows low CYP inhibition and minimal hERG activity. PD-L1-IN-8 can be used for the study of colon cancer [1].
    PD-L1-IN-8
  • HY-155681
    SWS1

    		PD-1/PD-L1 Monoamine Oxidase Cancer
    SWS1 is a d-(+)-biotin-conjugated PD-L1 inhibitor (IC50: 1.8 nM) with anticancer activity. SWS1 can increase the number of tumor-infiltrating lymphocytes and exhibit anti-tumor efficacy in the B16-F10 mouse model (TGI=66.1%) [1].
    SWS1
  • HY-179180
    PD-1/PD-L1-IN-59

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-59 (Compound MZ51) is a PD-1/PD-L1 inhibitor with an IC50 of 183 nM. PD-1/PD-L1-IN-59 can be used for the study of triple-negative breast cancer (TNBC) [1].
    PD-1/PD-L1-IN-59
  • HY-174424
    NPH16

    		PD-1/PD-L1 Apoptosis Cancer
    NPH16 is an orally active PD-1/PD-L1 inhibitor with an IC50 of 24.4 nM. NPH16 can promote HepG2 cell apoptosis. NPH16 shows excellent in vivo antitumor efficacy and favorable pharmacokinetic properties. NPH16 can be used for the study of liver cancer [1].
    NPH16
  • HY-P991620
    JS006

    		Transmembrane Glycoprotein Cancer
    JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) [1] .
    JS006
  • HY-169436
    Lon-TK

    		PD-1/PD-L1
    Lon-TK is a glycolysis inhibitor + linker conjugate of LTB (HY-169434). LTB is an intelligent responsive prodrug that connects Lonidamine (Lon) (HY-B0486) and a PD-L1 inhibitor (BMS-1, HY-19991) through a thioketal linker. It significantly inhibits the glycolytic metabolism of tumor cells and blocks the PD-1/PD-L1 immune escape pathway. Lon-TK shows potential for application in photodynamic-enhanced immunotherapy research [1].
    Lon-TK
  • HY-169392
    D5B

    		PD-1/PD-L1 Cancer
    D5B is a potent and selective PD-L1 inhibitor. D5B has been modified by DBCO. The EC50 of D5B degrading PD-L1 in 4T1 and B16-F10 tumor cells are 5.4 μM and 6.2 μM, respectively. D5B can block PD-L1/PD-1 interaction and has anti-tumor activity [1].
    D5B
  • HY-161605
    HBV/HDV-IN-2

    		HBV PD-1/PD-L1 Infection Inflammation/Immunology Cancer
    HBV/HDV-IN-2 (Compd 143) is a HBV, HDV and PD-1/PD-L1 inhibitor, with an EC50 of 35 nM for T cell activation [1].
    HBV/HDV-IN-2
  • HY-101097A
    PD-1-IN-17 TFA

    		PD-1/PD-L1 Cancer
    PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM [1].
    PD-1-IN-17 TFA
  • HY-W457085
    PD-1/PD-L1-IN-29 intermediate-2

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-29 intermediate-2 is an intermediate of PD-1/PD-L1 inhibitors and can be used to synthesize Antibody-Drug Conjugates (ADCs).
    PD-1/PD-L1-IN-29 intermediate-2
  • HY-161604
    HBV/HDV-IN-1

    		HBV PD-1/PD-L1 Infection Inflammation/Immunology Cancer
    HBV/HDV-IN-1 (Compd 122) is a HBV, HDV and PD-1/PD-L1 inhibitor, with EC50 values of 8 nM for T cell activation and 35 nM for PD-L1 internalization [1].
    HBV/HDV-IN-1
  • HY-48934
    PD-1/PD-L1-IN-29 intermediate-1

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-29 intermediate-1 is an intermediate of PD-1/PD-L1 inhibitors and can be used to synthesize Antibody-Drug Conjugates (ADCs).
    PD-1/PD-L1-IN-29 intermediate-1
  • HY-162357
    PD-L1-IN-5

    		PD-1/PD-L1 Cancer
    PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor, with the IC50 value of 785.6 nM. PD-L1-IN-5 has anti-tumor activity in vivo [1].
    PD-L1-IN-5
  • HY-W400801
    Denfivontinib hydrochloride

    G-749 hydrochloride

    		 TAM Receptor Cancer
    Denfivontinib (G-749) hydrochloride is an AXL inhibitor that has synergistic antitumor effects with the PD-1 inhibitor Pembrolizumab (HY-P9902). Denfivontinib can enhance the NOD-like receptor pathway, thereby promoting the formation of the NLRP3 inflammasome [1].
    Denfivontinib hydrochloride
  • HY-159101
    EP26

    		EGFR PD-1/PD-L1 Cancer
    EP26 is a potent and orally active EGFR and PD-L1 inhibitor with IC50 values of 48.6 nM, 1.77 µM, respectively. EP26 decreased the protein expression of p-EGFR. EP26 induces cell cycle arrest at G0/G1 phase. EP26 has the potential for the research of glioblastoma [1].
    EP26

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: